参考文献
[1]Chen W，Zhang L，Hu M，et al.Use of health technology assessment in drug reimbursement decisions in China[J].BMJ，2023，381:e068915.DOI:10.1136/bmj-2021-068915.
[2]Hauser SL，Bar-Or A，Cohen JA，et al.Ofatumumab versus Teriflunomide in Multiple Sclerosis[J].New England Journal of Medicine，2020 Aug 6；383（6）:546-557.
[3]Palace J，Bregenzer T，Tremlett H，et al.UK multiple sclerosis risk-sharing scheme:a new natural history dataset and an improved Markov model[J].BMJopen，2014，4（1）:e004073.
[4]Scandinavica AN.Course of multiple sclerosis.First results of a prospective study carried out of 102 MS patients from 1976-1980[J].Acta Neurologica Scandinavica，2010，65（4）:248-266.
[5]Orme M，Kerrigan J，Tyas D，et al.The effect of disease，functional status，and relapses on the utility of people with multiple sclerosis in the UK[J].Value in Health，2007，10（1）:54-60.
[6]Confavreux C，O'Connor P，Comi G，et al.Oral teriflunomide for patients with relapsing multiple sclerosis（TOWER）:a randomised，double-blind，placebo-controlled，phase 3 trial[J].The Lancet.Neurology，2014，13（3）:247-256.
[7]Samjoo IA，Worthington E，Drudge C，et al.Comparison of ofatumumab and other diseasemodifying therapies for relapsing multiple sclerosis:a network meta-analysis[J].Journal of Comparative Effectiveness Research，2020，9（18）:1255-1274.
[8]NLM.Economic Review[M/OL].In:Pharmacoeconomic report:ofatumumab（kesimpta）:（novartis pharmaceuticals Canada Inc.）:indication:multiple sclerosis，relapsing-remitting[internet].https://www.ncbi.nlm.nih.gov/books/NBK572535/.
[9]NICE.Ocrelizumab for treating primary progressive multiple sclerosis[EB/OL].（2019-06-12）[2023-08-31].https://www.nice.org.uk/guidance/TA585.
[10]Acaster S，Perard R，Chauhan D，et al.A forgotten aspect of the NICE reference case:an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis[J].Bmc Health Services Research，2013，13（1）:346.
[11]孙宇航，王萍.罕见病患者医疗保障的伦理思考[J].中国医学伦理学，2019，32（9）：1143-1146.
[12]Friedmann C，Levy P，Hensel P，et al.Using multi-criteria decision analysis to appraise orphan drugs:a systematic review[J].Expert Review of Pharmacoeconomics&Outcomes Research，2018，18（2）:135-146.
[13]北京协和医院罕见病多学科协作组，中国罕见病联盟.多准则决策分析应用于罕见病药品临床综合评价的专家共识（2022）[J].协和医学杂志，2022，13（2）：235-254.
[14]Kolasa K，Zwolinski KM，Kalo Z，et al.Potential impact of the implementation of multiplecriteria decision analysis（MCDA）on the Polish pricing and reimbursement process of orphan drugs[J].Orphanet Journal of Rare Diseases，2016，11（1）:1-12.
[15]Stafinski T，Glennie J，Young A，et al.HTA decision-making for drugs for rare diseases:comparison of processes across countries[J].Orphanet Journal of Rare Diseases，2022，17（1）:258.
[16]Korchagina D，Rémuzat C，Rodrigues J，et al.Health technology assessment，price and reimbursement review for orphan drugs In France[J].Value in Health，2014，17（7）:A540.(https://www.daowen.com)
[17]Nicod E，Annemans L，Bucsics A，et al.HTA programme response to the challenges of dealing with orphan medicinal products:Process evaluation in selected European countries[J].Health Policy，2019，123（2）:140-151.
[18]Nicod E，Jd KBB，Durand-Zaleski I，et al.Dealing with uncertainty and accounting for social value judgments in assessments of orphan drugs:evidence from four european countries[J].Value in Health，2017，20（7）:919-926.
[19]Ollendorf DA，Chapman RH，Pearson SD.Evaluating and valuing drugs for rare conditions:no easy answers[J].Value in Health，2018，21（5）:547-552.
[20]Kawalec P，Sagan A，Pilc A.The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe[J].Orphanet Journal of Rare Diseases，2016，11（1）:122.
[21]FIT Consulting.Challenges in preserving access to orphan drugs under an HTA framework[R/OL].（2021-12-02）[2023-06-26].https://www.fticonsulting.com/insights/reports/-/media/285673be00f84138ab72fad286b4f369.ashx.
[22]宣建伟，孙巧.中国罕见病药物经济学评估适用模型与支付阈值参考标准探讨[J].国际药学研究杂志，2019，46（9）：659-665.
[23]GLI.Pricing&Reimbursement Laws and Regulations|Korea[R].（2021-08-17）[2022-03-17].https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursementlaws-and-regulations/korea.
[24]Lee JH.Pricing and reimbursement pathways of new orphan drugs in South Korea:a longitudinal comparison[J].Healthcare，2021，9（3）:296.
[25]Fukuda T.Drug Pricing in Japan[M].Tokyo:Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health，2018.
[26]GLI.Pricing&Reimbursement Laws and Regulations|Japan[EB/OL].In:GLI.Global Legal Insights-International legal business solutions.https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations/japan.
[27]Martin Wenzl，Valérie Paris.Pharmaceutical Reimbursement and Pricing in Germany[R/OL].（2018-06）[2023-09-18].https://www.oecd.org/health/health-systems/Pharmaceutical-Reimbursement-and-Pricing-in-Germany.pdf.
[28]Gammie T，Lu CY，Babar UD，et al.Access to orphan drugs:a comprehensive review of legislations，regulations and policies in 35 countries[J].Plos One，2015，10（10）:e0140002.
[29]顾一纯，张琴华，黄镇，等.韩国高值罕用药使用保障机制[J/OL].中国卫生资源，2021，24（6）：641-645，825.
[30]Bae EY.Role of health technology assessment in drug policies:Korea[J].Value in Health Regional Issues，2019，18:24-29.
[31]Co-Chair LPG，Co-Chair ATMM，Andrew Briggs D，et al.Performance-based risk-sharing arrangements—good practices for design，implementation，and evaluation:report of the ISPOR good practices for performance-based risk-sharing arrangements task force[J].Value in Health，2013，16（5）:703-719.